EAU 2024 - Results from #80

Viewing 81-100 of 111 articles

Five-Year Interval Is Safe for Prostate Cancer Screening, Research Shows

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA Only - the PROBASE German Screening Trial in Young Men

EAU 2024: Development of the Bladder Utility Symptom Scale (BUSS Utility): A Novel Tool to Measure Utilities and Quality of Life in Bladder Cancer Patients

EAU 2024: Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer: PROGRxN-BCa

EAU 2024: Rapid Fire Debate 4: Patient with MIBC After Radical Cystectomy – Can We Use ctDNA to Guide Decisions on Adjuvant Chemo/IO? What About utDNA for Bladder Sparing After NAC?

EAU 2024: Towards Defining Follow-up Strategies for Patients with Primary EAU 2021 Intermediate-Risk Non-Muscle Invasive Bladder Cancer

EAU 2024: Defining Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Comparative Study of EAU and IBCG Criteria

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: MRI Only

EAU 2024: Rapid Fire Debate 3: Healthy Patient with T1HG Micropapillary NMIBC - What Is the Best Treatment Option? What If Mixed Histologic Subtypes in Addition to Micropapillary?

EAU 2024: European Urology Oncology Lecture: Survivorship Considerations Across the Spectrum of Genitourinary Oncology

EAU 2024: State-of-the-Art Lecture: Long-Term Toxicity in Testicular Cancer and AYA: Premature Mortality and Morbidity Illustrated

EAU 2024: Options and Challenges in the Management of Oligometastatic Prostate Cancer in the PSMA-PET Era

EAU 2024: Rapid Fire Debate 2: How Do We Manage a Patient with Frequent Recurrence of LG Papillary Tumours in the Bladder Despite Intravesical Chemotherapy and BCG Therapy? No Clinical Trial Available

EAU 2024: Extended Follow-up from CheckMate 274 Including the First Report of Overall Survival Outcomes

EAU 2024: Clinical Outcomes in Patients with High-Risk, Post-Cystectomy Muscle-Invasive Bladder Cancer with Persistent ctDNA- Status on Serial Testing: Surveillance Analysis from the IMvigor011 Study

EAU 2024: Disease Characterization: MRI in Evaluation After Neoadjuvant Chemotherapy

EAU 2024: Rapid Fire Debate 1: Is There Any Role for Urinary Markers Other than Cytology in Era of Modern Cystoscopy in Surveillance of Patients? What About to Decrease Frequency of Cystoscopy?

EAU 2024: Update on PSMA PET/CT: When Does Its Use in Staging Have an Impact on Survival?

EAU 2024: Controversies in Initial Staging for Renal Cell Cancer: Evaluation with Conventional Imaging Is Enough

EAU 2024: Disease Characterization: Are Biomarkers Better?

1
2
3
4
5
6